Monitoring MRI changes before and during Radiotherapy Treatment of Brain Tumors

Monitoring MRI changes before and during Radiotherapy Treatment of Brain Tumors - MRI during RT for brain tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON45550

Enrollment

Registered

2017-11-09

Start date

2018-01-16

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain metastasis Glioblastoma

Interventions

brain tumors

radiotherapy

1-3 extra MRIs

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Primary brain tumor (WHO IV, GBM); treated with fractionated radiotherapy with or without preceding surgery. - Brain metastasis from a solid extracranial tumor, eligible for treatment with fractionated radiotherapy with or without preceding surgery - Age 18 or older

Exclusion criteria

Exclusion criteria: - Patients receiving Whole brain radiation therapy (WBRT) - Patiens with a poor kidney function (GFR

Design outcomes

Primary

Measure	Time frame
- Difference in contrast enhancing tumor volume on Dynamic contrast-enhanced (DCE) sequences - Difference in location of the tumor. Measured by the shift of the centre of mass and the maximum distance between the tumor borders. - Difference in permeability of the blood vessels in the tumor - Difference in the perfusion rate in the tumor - Difference in diffusion (cellularity) of the tumor - Number of adjusted radiotherapy treatment plans in relation to peritumoral edema, the primary tumor and the tumor location	—

Measure

Time frame

- Difference in contrast enhancing tumor volume on Dynamic contrast-enhanced (DCE) sequences - Difference in location of the tumor. Measured by the shift of the centre of mass and the maximum distance between the tumor borders. - Difference in permeability of the blood vessels in the tumor - Difference in the perfusion rate in the tumor - Difference in diffusion (cellularity) of the tumor - Number of adjusted radiotherapy treatment plans in relation to peritumoral edema, the primary tumor and the tumor location

—

Secondary

Measure	Time frame
- Occurrence of side-effects due to radiotherapy, specifically the (time to) occurrence of radiation necrosis - Time to tumor progression - Overall survival	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)